Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5594411 | American Heart Journal | 2017 | 36 Pages |
Abstract
Udenafil was well-tolerated at all dosing levels. The 87.5 mg bid cohort achieved the highest plasma drug level and was associated with a suggestion of improvement in myocardial performance. These data suggest that the 87.5 mg bid regimen may be the most appropriate for a Phase III clinical trial.
Keywords
CmaxMPIRHIPediatric Heart NetworkPHNPDE5AUCPeripheral arterial tonometrytwice dailyAugmentation indexMyocardial performance indexReactive hyperemia indexPVRadverse eventmaximal concentrationpharmacokineticphosphodiesterase type 5Average concentrationPulmonary vascular resistancearea under the curvemillilitersmilligramspatBIDquality control
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
David J. MD, Victor PhD, Bryan H. MD, Shan MA, Michelle S. MS, Elizabeth A. RN, Eileen BS, Seema MD, Shaji C. MD, Kurt R. MD, R. Mark MD, Mario PhD, Jonathan R. MD, Tina M. PhD, James L. RPh, PhD, Stephen M. MD,